Navigation Links
Sangui BioTech International, Inc. Files Remaining Reports

Shareholders' Meeting to be Held on October 9, 2008

WITTEN, Germany, September 8 /PRNewswire/ -- On Wednesday, August 27, 2008, Sangui BioTech International, Inc., filed with the SEC its financial statements on Form 10KSB for the 2007 financial year (ended June 30, 2007) as well as the quarterly reports on Forms 10QSB for the quarters ended September 30, 2007, December 31, 2007 as well as March 31, 2008. The company is now current with its SEC filings.

The Board of Directors has set the date for the forthcoming shareholders' meeting at October 9, 2007 at 11 a.m. Central European Time. It will take place in Witten, Germany. The preliminary agenda and proxy statement are available on the corporate website All documents as well as the date of the meeting are subject to SEC approval, Shareholders will be informed of any changes via the corporate website.

SanguiBioTech GmbH is a wholly owned subsidiary of Sangui BioTech International, Inc. ( SGBI)

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information please contact:

Joachim Fleing

Phone: +49-160-741-27-17

Fax: +49-2302-915-191


SOURCE Sangui Bio Tech International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sangui Partnership Enters a New Phase:
2. Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses
3. Investors Acquire Share in Sangui BioTech GmbH
4. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
5. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
6. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
7. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
8. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
9. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
10. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
11. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
Post Your Comments:
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
Breaking Biology Technology:
(Date:5/12/2016)... -- , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: ) ... provide their customers enhanced security to access and ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):